LivaNova (NASDAQ:LIVN) Upgraded by Robert W. Baird to “Outperform”

Robert W. Baird upgraded shares of LivaNova (NASDAQ:LIVN) from a neutral rating to an outperform rating in a report published on Tuesday morning, MarketBeat Ratings reports. Robert W. Baird currently has $66.00 target price on the stock, up from their previous target price of $55.00.

Several other equities research analysts have also weighed in on LIVN. Stifel Nicolaus lifted their price target on LivaNova from $70.00 to $72.00 and gave the company a buy rating in a research report on Thursday, July 25th. Needham & Company LLC upped their price target on LivaNova from $72.00 to $75.00 and gave the company a buy rating in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Buy and an average target price of $70.80.

LivaNova Stock Performance

Shares of NASDAQ LIVN opened at $50.75 on Tuesday. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -84.58 and a beta of 1.00. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The stock’s 50-day moving average is $48.85 and its 200 day moving average is $53.37.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.15. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. The business had revenue of $318.60 million for the quarter, compared to analysts’ expectations of $305.05 million. On average, sell-side analysts anticipate that LivaNova will post 2.58 EPS for the current fiscal year.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Campbell & CO Investment Adviser LLC bought a new stake in LivaNova during the 4th quarter valued at approximately $2,090,000. Trexquant Investment LP purchased a new position in LivaNova during the 4th quarter valued at approximately $1,079,000. Norges Bank purchased a new position in LivaNova during the 4th quarter valued at approximately $26,064,000. BNP Paribas Financial Markets grew its holdings in LivaNova by 88.6% during the 1st quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock valued at $2,356,000 after buying an additional 19,783 shares in the last quarter. Finally, Great Lakes Advisors LLC purchased a new position in LivaNova during the 2nd quarter valued at approximately $16,614,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.